Clindamycin foam - Stiefel Laboratories
Alternative Names: 1% Clindamycin phosphate foam; 1% Evoclin foam; EvoclinLatest Information Update: 24 Dec 2021
At a glance
- Originator Stiefel Laboratories
- Class Antibacterials; Lincosamides; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Acne vulgaris
- No development reported Folliculitis
Most Recent Events
- 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
- 28 Dec 2006 Connetics Corporation has been acquired and merged into Stiefel Laboratories
- 14 Apr 2005 Connetics and Ventiv Health have entered into an agreement to co-promote Evoclin™ in USA for acne vulgaris